The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections
| Autor: | Edward Campanaro, Barry I. Eisenstein, Francis P. Tally, Dennis G. Maki, Investigators, Robert D. Arbeit |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Microbiology (medical)
Adult Male medicine.medical_specialty Streptomyces roseosporus medicine.drug_class Antibiotics Penicillins Benzylpenicillin chemistry.chemical_compound Daptomycin Vancomycin Internal medicine medicine Humans Skin Diseases Infectious Adverse effect Infusions Intravenous Antibacterial agent Aged biology business.industry Soft Tissue Infections Lipopeptide Middle Aged biology.organism_classification Surgery Anti-Bacterial Agents Infectious Diseases Treatment Outcome chemistry Female business medicine.drug |
| Zdroj: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 38(12) |
| ISSN: | 1537-6591 |
| Popis: | Daptomycin is the first available agent from a new class of antibiotics, the cyclic lipopeptides, that has activity against a broad range of gram-positive pathogens, including organisms that are resistant to methicillin, vancomycin, and other currently available agents. Daptomycin (4 mg/kg intravenously [iv] every 24 h for 7-14 days) was compared with conventional antibiotics (penicillinase-resistant penicillins [4-12 g iv per day] or vancomycin [1 g iv every 12 h]) in 2 randomized, international trials involving 1092 patients with complicated skin and skin-structure infections. Among 902 clinically evaluable patients, clinical success rates were 83.4% and 84.2% for the daptomycin- and comparator-treated groups, respectively (95% confidence interval, -4.0 to 5.6). Among patients successfully treated with iv daptomycin, 63% required only 4-7 days of therapy, compared with 33% of comparator-treated patients (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|